Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Living Modified Organism
(LMO)
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
Vaccine against Aujeszky's Disease
EN
Not available
No
-
Organization:Vemie Veterinär Chemie GmbH ()Tackweg 11Tönisvorst,
47918, GermanyPhone: +49-2151-993300 ,Fax: +49-2151-993322 ,Email:Website:
Two genes (glycoprotein gene and thymidine kinase gene) of the Pseudorabies virus (PRV) were deleted in this LMO to produce the animal vaccine "Nobi-Porvac Aujeszky live (gl, tk) (with Diluvac forte)". This vaccine is intended for immunisation of pigs against Aujeszky disease.
EN
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
-
BCH-ORGA-SCBD-100338-4 Organism Suid alphaherpesvirus 1 (SHV-1)Viruses
SHV-1 strain used is Begonia
EN
EN
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
-
BCH-GENE-SCBD-103649-1 gI Glycoprotein | Suid alphaherpesvirus 1 (SHV-1)Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
-
BCH-GENE-SCBD-103650-1 PK Protein Kinase | Suid alphaherpesvirus 1 (SHV-1)Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
The gI and PK genes are deleted from the native SHV-1 to produce an attenuated virus to be used as a vaccine.
EN
EN
- Vaccine
EN
EN
Loading...
